Clinical Trial Update: A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP) [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of ASP0598 Otic Solution for chronic tympanic membrane perforation was terminated, and results were posted on 2024-02-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tympanic Membrane Perforation

Drugs mentioned

• ASP0598 Otic Solution (ASP0598)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Chronic Tympanic Membrane Perforation | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-02-07